产品名称
18:1 PEG1000 PE, Avanti Research™ - A Croda Brand 880730P, powder
assay
>99% (TLC)
form
powder
packaging
pkg of 2 × 100 mg (880730P-200mg), pkg of 1 × 25 mg (880730P-25mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 880730P
shipped in
dry ice
storage temp.
−20°C
SMILES string
[H][C@@](COP([O-])(OCCNC(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)=O)(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O.[NH4+]
InChI
1S/C87H168NO32P.H3N/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-85(89)117-82-84(120-86(90)35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-5-2)83-119-121(92,93)118-37-36-88-87(91)116-81-80-115-79-78-114-77-76-113-75-74-112-73-72-111-71-70-110-69-68-109-67-6
InChI key
GAPHFOOXSGWGKG-QOYAZRIPSA-N
Application
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] (18:1 PEG1000 PE) is suitable for fluorescent PEG-grafted liposomes/fluorescent stealth liposomes or liposomes.
Biochem/physiol Actions
Polyethylene glycol (PEG) conjugated phospholipids are known to protect the steric nature of liposomes. Hence, they are commonly recommended for use in liposome formulation.
Packaging
5 mL Clear Glass Sealed Ampule (880730P-200mg)
5 mL Clear Glass Sealed Ampule (880730P-25mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
存储类别
11 - Combustible Solids
wgk
WGK 3
Surface-grafted polyethylene glycol conformation impacts the transport of PEG-functionalized liposomes through a tumour extracellular matrix model
Labouta HI, et al.
Royal Society of Chemistry Advances, 8(14), 7697-7708 (2018)
Have Aliu et al.
International journal of nanomedicine, 12, 8377-8388 (2017-12-05)
Immunotherapy by sublingual administration of allergens provides high patient compliance and has emerged as an alternative to subcutaneous immunotherapy for the treatment of IgE-associated allergic diseases. However, sublingual immunotherapy (SLIT) can cause adverse events. Development of allergen delivery systems enabling
G F Peacock et al.
Drug delivery, 10(1), 29-34 (2003-01-30)
A new cholesterol-carborane conjugate (BCH) has been synthesized as a potential targeting agent for boron neutron capture therapy (BNCT) of cancers. The compound is extremely water insoluble and was formulated in two liposomal formulations to determine if the compound could
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 880730P-200MG | 04061835188246 |
| 880730P-25MG | 04061835188253 |